A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...

About one out of every eight adults in the U.S. has taken a GLP-1 medication, such as Trulicity, Ozempic, Rybelsus or Mounjaro — and half of these people are still ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

For individuals living with type 2 diabetes or struggling with weight loss, Rybelsus has become a popular name in the realm of oral GLP-1 receptor agonists. While its effectiveness in lowering blood ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...